Skip to main content
  • Main menu
  • User menu
  • Search
  • English ▼
    • English
    • Afrikaans
    • Albanian
    • Amharic
    • Arabic
    • Armenian
    • Azerbaijani
    • Basque
    • Belarusian
    • Bengali
    • Bosnian
    • Bulgarian
    • Catalan
    • Cebuano
    • Chichewa
    • Chinese (Simplified)
    • Chinese (Traditional)
    • Corsican
    • Croatian
    • Czech
    • Danish
    • Dutch
    • Esperanto
    • Estonian
    • Filipino
    • Finnish
    • French
    • Frisian
    • Galician
    • Georgian
    • German
    • Greek
    • Gujarati
    • Haitian Creole
    • Hausa
    • Hawaiian
    • Hebrew
    • Hindi
    • Hmong
    • Hungarian
    • Icelandic
    • Igbo
    • Indonesian
    • Irish
    • Italian
    • Japanese
    • Javanese
    • Kannada
    • Kazakh
    • Khmer
    • Korean
    • Kurdish (Kurmanji)
    • Kyrgyz
    • Lao
    • Latin
    • Latvian
    • Lithuanian
    • Luxembourgish
    • Macedonian
    • Malagasy
    • Malay
    • Malayalam
    • Maltese
    • Maori
    • Marathi
    • Mongolian
    • Myanmar (Burmese)
    • Nepali
    • Norwegian
    • Pashto
    • Persian
    • Polish
    • Portuguese
    • Punjabi
    • Romanian
    • Russian
    • Samoan
    • Scottish Gaelic
    • Serbian
    • Sesotho
    • Shona
    • Sindhi
    • Sinhala
    • Slovak
    • Slovenian
    • Somali
    • Spanish
    • Sudanese
    • Swahili
    • Swedish
    • Tajik
    • Tamil
    • Telugu
    • Thai
    • Turkish
    • Ukrainian
    • Urdu
    • Uzbek
    • Vietnamese
    • Welsh
    • Xhosa
    • Yiddish
    • Yoruba
    • Zulu

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

English ▼
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scottish Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sudanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
OtherTEACHING EDITORIAL

Applying Nuclear Regulatory Commission Guidelines to the Release of Patients Treated with Sodium Iodine-131

William K. Tuttle and Paul H. Brown
Journal of Nuclear Medicine Technology December 2000, 28 (4) 275-279;
William K. Tuttle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1.

    Summary of Release Criteria, Required Instructions to Patients, and Records to Be Maintained*

    Patient groupBasis for releaseCriteria for releaseInstructions neededRelease records required
    All patients, including patients who are breastfeeding1. Administered activity   2. Retained activityAdministered activity of 131I <33 mCi Retained activity of 131I <33 mCiYes, if administered 131I >7 mCi Yes, if retained 131I >7 mCiNo   Yes, see Regulatory Guide
    3. Measured dose rateMeasured dose rate from 131I <7 mrem/hYes, if dose rate 131I >2 mrem/hYes, see Regulatory Guide
    4. Patient-specific calculations131I calculated dose to other than patient <500 mremYes, if calculated 131I dose >100 mremYes, see Regulatory Guide, and discussed below
    Patients who are breastfeedingAll the above bases for releaseYes, complex, see Regulatory GuideYes, complex, see Regulatory Guide
    • ↵* Synopsis of Table 4 from U.S. Nuclear Regulatory Guide 8.39.

    • View popup
    TABLE 2.

    Uptake Fractions and Effective Half-Lives for Iodine-131*

    Medical conditionExtrathyroidal componentThyroidal component
    Uptake fraction F1Effective half-life T1eff (day)Uptake fraction F2Effective half-life T2eff (day)
    Hyperthyroidism0.200.320.805.2
    Post-thyroidectomy for thyroid cancer0.950.320.057.3
    • ↵* From Table B-1 in NRC Regulatory Guide 8.39.

    • View popup
    APPENDIX A

    Radioiodine Therapy Outpatient Worksheet

    Patient's Name   Patient ID Number 
    1. Will the administered activity of 131I exceed 33 mCi?
      No→The patient may be treated as an outpatient. Ensure that written and oral patient instructions are provided, and a written directive completed.
      Yes→The patient may require hospitalization for treatment. Continue to Item 2.
    2. Determine if the following criteria apply:
      YesNo
      □□The patient will maintain a prudent distance from others for at least the first 2 days.
      □□The patient will sleep alone in a room for at least the first night.
      □□The patient will not travel by airplane or mass transportation for at least the first day.
      □□The patient will not travel on a prolonged automobile trip with others for at least the first 2 days.
      □□The patient will have sole use of a bathroom for at least the first 2 days.
      □□The patient will drink plenty of fluids for at least the first 2 days.
    3. If the answer is No to any one or more of the criteria in Item 2 above, the patient must be hospitalized for treatment if the administered activity exceeds 33 mCi 131I.
    4. If the answer is Yes to all of the criteria in Item 2, perform the necessary calculations in Item 5, below, to determine whether the patient can be released immediately in accordance with NRC Regulatory Guide 8.39, Appendix B, as discussed below.
    5. Patient-specific dose calculations (Check 1 of the 3 boxes, whichever applies, and calculate D).
    □ For Na131I treatment of a patient post-thyroidectomy for thyroid cancer:
    D (mrem) = 2.27 Qo = ________ mrem,
      where D (mrem) is the maximum likely dose to an individual exposed to the patient and Qo is the administered activity in millicuries (e.g., if you administer 100 mCi to the patient, then D (mrem) = 2.27 ∗ 100 = 227 mrem).
    □ For Na131I treatment of hyperthyroidism:
    D (mrem) = 8.84 Qo = ________ mrem,
      where D (mrem) is the maximum likely dose to an individual exposed to the patient and Qo is the administered activity in millicuries.
     Note: the above 2 calculations use occupancy factors discussed in Appendix B, section B.1.2 of NRC Regulatory Guide 8.39, and effective half-lives and uptake components found in Table B-1 of NRC Regulatory Guide 8.39. If you use other values, as determined for your specific patient, you must use Equation B-5 of the Regulatory Guide. You must write the entire equation below:
    □ D (mrem) =
    6. Answer the following:
      YesNo
      □□The maximum likely dose to an individual exposed to the patient [D (mrem)] is less than 500 millirem?
    If yes, the patient may be released. Keep this worksheet (including any other calculations) and a copy of the patient instructions for documentation of compliance with 10 CFR 35.75.
    7. Further restrictions apply if the patient is breast-feeding (see Regulatory Guide).
      YesNo
      □□This patient is breast-feeding an infant or child.
    Worksheet completed by _____________Date ____________________
    (Signature)
    • View popup
    APPENDIX B

    Instructions to Patients Containing More Than 6.9 mCi Na131I Released from the Medical Center

    Patient name __________ Patient ID number __________ .
    _____ mCi of Na131I was administered orally at _____ am/pm on ___ / ___ / ___ .
    Patient released from the medical center at __________ am/pm on ___ / ___ / ___ .
    Patient and Family Learning Needs
    The patient:
     □ does not have special learning considerations.
     □ has special learning considerations which will change the method of instruction (specify if present).
    Patient and Family Instructions
    (write additional instructions on the back as needed)
    Safe and effective use of medications.
     1. Resume previous thyroid medications as follows:
    Diet and nutrition.
     1. Do not eat for 2 hours following the administration of Na131I, however you may drink clear liquids (water, coffee, tea, fruit juices, and/or soft drinks).
     2. Drink as much fluid as tolerable for 48 hours following administration.
     3. Chew gum, or suck on hard or sour candy, frequently for 48 hours to encourage the flow of saliva.
     4. Use disposable cups, plates, and other dishes and tableware for ___ days.
    Suggestions to minimize the radiation dose to other people.
     1. Avoid sustained close contact with other people for ___ days, especially infants, children, and pregnant women. Remember that radioactive contamination may spread to others through your perspiration, saliva, urine, and feces.
     2. Sleep alone for ___ days.
     3. Avoid conception for 6 months.
    Personal hygiene and grooming.
     1. Urinate frequently (every 2 hours if possible) for ___ days. Men need to sit down to urinate during this time.
     2. Flush the toilet twice after each use and keep your hands clean for ___ days.
     3. Shower daily and use separate towels for ___ days.
     4. Wear clothing that can be laundered (not dry cleaned) for ___ days.
     5. After ___ days wash your clothing, towels, and bedding separately (put through wash/rinse cycles twice).
     6. In the rare chance you should vomit within 2 hours of receiving therapy, use paper towels to soak up the material and flush it down the toilet. Try not to spread the material around, as it will be radioactive. Wash your hands. Inform the nuclear medicine staff as soon as possible at __________  [telephone number].
    Special Instructions:
    If you experience any of the following symptoms, contact your physician:
     Increased shakiness
     Rapid heart rate
     Shortness of breath
     Increasing pain or swelling in the neck over the next 2–3 weeks
     Difficulty breathing.
    Important Telephone Numbers
     After hours urgent calls can be made to the Medical Center Operator at __________ and ask the operator to connect you to the Emergency Care Unit at ext. ___ .
     During normal business hours (8:00 am–4:30 pm) call Nuclear Medicine at __________ .
     If you have an Emergency, call 911.
    Additional Instructions:
    Follow-Up Appointments
    ClinicConfirmed date and timeSpecial instructionsInitials
    I have reviewed the release instructions with the patient and/or family or caregiver. The patient or caregiver was able to verbalize understanding of the instructions. A copy of these written instructions was given to the patient or caregiver.
    Name __________ Date ___ Time ___ am/pm
       (Person giving the instructions)
    Release instructions have been explained to me and/or my family or caregiver. I have received a copy of the instructions and I understand them.
    Name __________ Date ___
       Circle one: Patient/Family/Caregiver signature
    Place the original in the medical record and give the patient and/or family 1 copy.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 28 (4)
Journal of Nuclear Medicine Technology
Vol. 28, Issue 4
December 1, 2000
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Share
Applying Nuclear Regulatory Commission Guidelines to the Release of Patients Treated with Sodium Iodine-131
William K. Tuttle, Paul H. Brown
Journal of Nuclear Medicine Technology Dec 2000, 28 (4) 275-279;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
  • 131I in Blood Samples: A Danger for Professionals? A Problem for Immunoassays?
  • Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy
  • Online Regulatory Guide Errors
  • Online Regulatory Guide Errors
  • Google Scholar

More in this TOC Section

  • Fear in the Patient with Undiagnosed Symptoms
  • Quality Control Testing of Dose Calibrators
Show more Teaching Editorial

Similar Articles

  • Release of Patients Containing Therapeutic Dosages of Iodine-131 from Hospitals
  • 45TH ANNUAL MEETING: TECHNOLOGIST SECTION PROGRAM: Proceedings of the 45th Annual Meeting of The Society of Nuclear Medicine June 7–11, 1998—Toronto, Ontario, Canada
  • 44TH ANNUAL MEETING: TECHNOLOGIST SECTION PROGRAM: Proceedings of the 44th Annual Meeting of The Society of Nuclear Medicine June 1–4, 1997 • San Antonio, Texas
  • Problem-Based Learning in Nuclear Medicine Technology Education
  • Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy
See more
SNMMI

© 2025 SNMMI

Powered by HighWire
Alerts for this Article
Sign In to Email Alerts with your Email Address
Email this Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Applying Nuclear Regulatory Commission Guidelines to the Release of Patients Treated with Sodium Iodine-131
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Applying Nuclear Regulatory Commission Guidelines to the Release of Patients Treated with Sodium Iodine-131
William K. Tuttle, Paul H. Brown
Journal of Nuclear Medicine Technology Dec 2000, 28 (4) 275-279;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.